NMN vs NR: Which NAD+ Supplement Actually Works? (2026)

NAD+ fuels mitochondrial energy and is the sole substrate for the DNA repair enzyme PARP and for the sirtuins (Massudi et al., 2012). Levels fall with age: in human skin, NAD+ was significantly lower in adults, older adults and the elderly than in newborns (Massudi), and a gradual decline in tissue NAD+ is documented in rodents and humans (Covarrubias et al., 2021). Two precursors, NMN and NR, promise to restore them. This deep dive covers the biochemistry, clinical evidence, FDA's 2025 reversal on NMN, and our Longevity Stack recommendations.

Why you can't just take NAD+

NAD+ is too large to pass through cell membranes and gets degraded in the gut. IV infusions work but cost $500-1,000+ per session. That's why the field uses precursors. The conversion pathway: NR → NMN → NAD+, with the enzyme NRK1 rate-limiting for both precursors; in cell studies, extracellular NMN is first converted to NR before it is taken up (Ratajczak et al., 2016). Nicotinamide (NAM), which NR breaks down into, re-enters NAD+ synthesis by a separate salvage route. NR crosses cell membranes through equilibrative nucleoside transporters ENT1, ENT2 and ENT4 (Kropotov et al., 2021). NMN's proposed transporter, Slc12a8, was reported in mouse gut in 2019 (Grozio et al., 2019) and was challenged in the same journal (Schmidt and Brenner, 2019); it remains contested.

As an Amazon Associate I earn from qualifying purchases.

Head-to-head

The case for NMN

Proximity: One enzymatic step from NAD+. David Sinclair (Harvard) takes NMN himself. Unique benefits: In a 10-week randomized trial, 250mg/day of NMN increased muscle insulin sensitivity in postmenopausal women with prediabetes who were overweight or obese (Yoshino et al., Science 2021). The weight gain suppression and enhanced eye function come from a 12-month study in mice (Mills et al., 2016). Across 15 human trials at 250 to 2,000mg/day, a 2026 meta-analysis found NMN well tolerated but saw no significant effect on body weight, BMI, fasting glucose or HbA1c, with a slight drop in diastolic blood pressure (Yang et al., 2026). Stability: More stable in blood than NR. The FDA saga, now resolved in NMN's favour: In November 2022 FDA took the position that NMN was excluded from the dietary supplement definition because it had been authorized for investigation as a new drug, and for almost three years NMN was largely sold as a "research compound." On 29 September 2025 FDA reversed course: it accepted evidence that NMN was marketed as a dietary supplement in the US as early as 2017, before the drug investigation, and concluded that NMN is not excluded from the dietary supplement definition (FDA response to citizen petition, docket FDA-2023-P-0872). On 2 December 2025 FDA set aside its 2022 letter and reinstated its May 2022 acknowledgement, without objection, of a new dietary ingredient notification for NMN (FDA letter, 2 December 2025).

The case for NR

Clear entry: NR crosses cell membranes through equilibrative nucleoside transporters and is then phosphorylated by the NRK1 enzyme (Kropotov et al., 2021; Ratajczak et al., 2016). Far less debate than NMN's route. GRAS status: FDA had no questions about ChromaDex's GRAS notice for nicotinamide riboside chloride as a source of vitamin B3 in foods and drinks (FDA GRN 635, closed August 2016), and NR is sold as a dietary supplement in the US. Neuroprotection, promising then tested: A 2023 Aging Cell study of 22 healthy older adults taking 500mg twice daily for 6 weeks found NR raised NAD+ and lowered Aβ42, pJNK and pERK1/2 in blood vesicles enriched for neuronal origin (Vreones et al., 2023). The first large outcome trial was a setback: in the 2026 NOPARK phase 3 trial, 410 people with early Parkinson disease took 500mg twice daily or placebo for 52 weeks, and NR did not improve clinical outcomes and scored worse than placebo on the main disease rating scale (Brakedal et al., JAMA 2026). The catch: Much of it is cleaved to nicotinamide (vitamin B3) by the enzyme purine nucleoside phosphorylase; in mice, blocking that enzyme kept NR levels high in blood (Kropotov et al., 2022), so some argue you're paying premium prices for expensive B3.

Best supplements

Best NR value: Life Extension NAD+ Cell Regenerator ($40.50/30 servings, $1.35/day)

Same ChromaDex Niagen ingredient as Tru Niagen, often at a lower price. Life Extension's quality earned our saffron and berberine picks too.

Best NMN: ProHealth Longevity NMN Pro 500 ($42.95/30 servings, $1.43/day)

500mg of Uthever NMN per capsule, every batch third-party tested in US laboratories, sold as an "Enhanced Absorption" formula (ProHealth's label lists hypromellose capsules and does not claim an enteric coating). Since FDA's September 2025 reversal, NMN is a lawful dietary supplement ingredient in the US again.

Stacking with the Longevity Stack

+ TMG: Cheap insurance rather than a must. Clearing the extra nicotinamide uses methyl groups, which is the theory behind adding TMG, but in a placebo-controlled trial high-dose NR for up to 30 days had no impact on DNA methylation, including in people with MTHFR variants (Gaare et al., 2023). + Resveratrol: Sold as a sirtuin activator, the enzymes that need NAD+ as fuel, though whether it activates SIRT1 directly is disputed (Pacholec et al., 2010). + Omega-3: Take together with fat for absorption. + Curcumin: Anti-inflammatory + anti-aging stack.

Safety: what the trials show

NMN: Across 10 randomized trials with safety data (250 to 2,000mg/day, 14 days to 24 weeks), NMN did not increase overall or serious adverse events and did not raise liver enzymes (Yang et al., 2026). Long-term human safety data do not exist yet.

NR: 2,000mg/day for 12 weeks was well tolerated in obese men with normal safety blood tests (Dollerup et al., 2018). If you have Parkinson disease, note that in the 52-week NOPARK trial NR at 1,000mg/day was associated with worse clinical scores than placebo (Brakedal et al., 2026); talk to your neurologist before taking it.

Neither precursor has been studied in pregnancy or breastfeeding, and FDA does not review supplements for effectiveness before sale.

Health Britannica's position

We recommend NR (Tru Niagen or Life Extension) as the default, well-mapped cellular entry, an FDA GRAS letter, the deepest safety record (2,000mg/day for 12 weeks was well tolerated in obese men, Dollerup et al., 2018), and the most human trial data, though the 2026 NOPARK result means we no longer count neuroprotection as a reason to choose it. If you're drawn to NMN's one-step proximity and Sinclair's endorsement, ProHealth is the recommended NMN product, and since FDA's September 2025 reversal there is no longer a regulatory gray area to accept. What matters more than which precursor: consider TMG as cheap insurance, maintain Foundation Stack basics, and pair with the full Longevity Stack.

Sources

1. US Food and Drug Administration. Response to citizen petition on the regulatory status of beta nicotinamide mononucleotide, docket FDA-2023-P-0872 (29 September 2025). Accessed 19 October 2026.
2. US Food and Drug Administration. Letter on NMN new dietary ingredient notifications 1240 and 1247 (2 December 2025). Accessed 19 October 2026.
3. US Food and Drug Administration. GRAS Notice 635, nicotinamide riboside chloride. Accessed 19 October 2026.
4. Brakedal B et al. Nicotinamide riboside for patients with early-stage Parkinson disease: the NOPARK randomized clinical trial. JAMA. 2026. Accessed 19 October 2026.
5. Yang W et al. Safety and metabolism-related outcomes of oral nicotinamide mononucleotide supplementation in adults: a systematic review and meta-analysis. Nutrients. 2026. Accessed 19 October 2026.
6. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. Accessed 19 October 2026.
7. Mills KF et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016. Accessed 19 October 2026.
8. Vreones M et al. Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. Aging Cell. 2023. Accessed 19 October 2026.
9. Dollerup OL et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men. Am J Clin Nutr. 2018. Accessed 19 October 2026.
10. Trammell SA et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016. Accessed 19 October 2026.
11. Liao B et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. J Int Soc Sports Nutr. 2021. Accessed 19 October 2026.
12. Ratajczak J et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat Commun. 2016. Accessed 19 October 2026.
13. Kropotov A et al. Equilibrative nucleoside transporters mediate the import of nicotinamide riboside and nicotinic acid riboside into human cells. Int J Mol Sci. 2021. Accessed 19 October 2026.
14. Kropotov A et al. Purine nucleoside phosphorylase controls nicotinamide riboside metabolism in mammalian cells. J Biol Chem. 2022. Accessed 19 October 2026.
15. Grozio A et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019. Accessed 19 October 2026.
16. Schmidt MS, Brenner C. Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nat Metab. 2019. Accessed 19 October 2026.
17. Massudi H et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012. Accessed 19 October 2026.
18. Covarrubias AJ et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021. Accessed 19 October 2026.
19. Gaare JJ et al. Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease. iScience. 2023. Accessed 19 October 2026.
20. Pacholec M et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010. Accessed 19 October 2026.